β受体阻滞剂和钙通道阻滞剂：一线药物。

Beta-Blockers and Calcium Channel Blockers: First Line Agents.

作者信息

Pascual Isaac, Moris Cesar, Avanzas Pablo

机构信息

Área del Corazón, Hospital Universitario Central de Asturias, Avenida de Roma, s/n, 33011, Oviedo, Asturias, Spain.

出版信息

Cardiovasc Drugs Ther. 2016 Aug;30(4):357-365. doi: 10.1007/s10557-016-6682-1.

DOI:10.1007/s10557-016-6682-1

PMID:27576497

Abstract

Beta-blockers and calcium channel blockers (CCB) are milestones in the treatment of stable coronary ischaemic disease. Their main effects are particularly suited for the management of effort-induced angina because of the reduction of oxygen demand they achieve. The clinical benefits of these drugs are highly reproducible and have been shown to improve overall clinical outcomes. Despite the availability of other, and newer antianginal drugs, treatment guidelines continue to recommend the use of beta-blockers and calcium channel blockers as first line therapies.

摘要

β受体阻滞剂和钙通道阻滞剂（CCB）是稳定型冠状动脉缺血性疾病治疗中的里程碑。由于它们能降低氧需求，其主要作用特别适用于劳力性心绞痛的管理。这些药物的临床益处具有高度可重复性，并已证明能改善总体临床结局。尽管有其他更新的抗心绞痛药物，但治疗指南仍继续推荐使用β受体阻滞剂和钙通道阻滞剂作为一线治疗药物。